Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement

被引:0
作者
O'Brien, Diana A. Roth [1 ]
Braunstein, Lior Z. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
关键词
Breast cancer; hypofractionation; partial breast irradiation; radiotherapy; whole breast irradiation; POSTMASTECTOMY RADIATION-THERAPY; LUMPECTOMY PLUS TAMOXIFEN; 20-YEAR FOLLOW-UP; CONSERVING SURGERY; HYPOFRACTIONATED RADIOTHERAPY; POSTOPERATIVE RADIOTHERAPY; ADJUVANT RADIOTHERAPY; PREMENOPAUSAL WOMEN; UK STANDARDIZATION; ESTROGEN-RECEPTOR;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiotherapy (RT) is a crucial component of the adjuvant treatment of breast cancer that often follows breast conservation or mastectomy to further reduce the risk of local recurrence. As outcomes improve and our understanding of disease biology advances, interest is growing in de-escalating RT to minimize the treatment burden and side effects while maintaining oncologic outcomes. This review examines the evidence and summarizes the results of ongoing trials evaluating RT de-escalation strategies in breast cancer. We discuss hypofractionation and ultrahypofractionation for whole breast irradiation, showing efficacy comparable with that of conventional fractionation with improved convenience. The role of accelerated partial breast irradiation is explored, with an emphasis on its benefits and the importance of patient selection. We review data supporting omission of RT in selected patients with low-risk, early-stage disease, particularly older women with hormone receptor-positive disease. Ongoing research into biomarker-guided RT de-escalation is addressed, including trials using genomic assays and immunohistochemistry. Emerging data on RT de-escalation in HER2-positive and triple-negative breast cancers are discussed. Finally, we explore de-escalation strategies for locally advanced disease, including hypofractionation for post-mastectomy RT and potential omission of regional nodal irradiation after neoadjuvant chemotherapy for those with an excellent response. These strategies may allow more personalized approaches to RT, potentially improving quality of life without compromising oncologic outcomes.
引用
收藏
页码:30 / 39
页数:10
相关论文
共 104 条
  • [1] Partial breast irradiation: when less could be more
    Alvim Ambrosio, Alexandre Vasconcellos
    Melo Gondim, Guilherme Rocha
    Inocente Inacio, Murilo Jose
    de Assis Pellizzon, Antonio Cassio
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 : S56 - S61
  • [2] Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy
    Arvold, Nils D.
    Taghian, Alphonse G.
    Niemierko, Andrzej
    Raad, Rita F. Abi
    Sreedhara, Meera
    Nguyen, Paul L.
    Bellon, Jennifer R.
    Wong, Julia S.
    Smith, Barbara L.
    Harris, Jay R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (29) : 3885 - 3891
  • [3] Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
    Barton, S.
    Zabaglo, L.
    A'Hern, R.
    Turner, N.
    Ferguson, T.
    O'Neill, S.
    Hills, M.
    Smith, I.
    Dowsett, M.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1760 - 1765
  • [4] De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer
    Bazan, Jose G.
    Jhawar, Sachin R.
    Stover, Daniel
    Park, Ko Un
    Beyer, Sasha
    Healy, Erin
    White, Julia R.
    [J]. NPJ BREAST CANCER, 2021, 7 (01)
  • [5] Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
    Bellon, Jennifer R.
    Tayob, Nabihah
    Yang, David D.
    Tralins, Jordan
    Dang, Chau T.
    Isakoff, Steven J.
    DeMeo, Michelle
    Burstein, Harold J.
    Partridge, Ann H.
    Winer, Eric P.
    Krop, Ian E.
    Tolaney, Sara M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (01): : 117 - 124
  • [6] Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
    Bellon, Jennifer R.
    Guo, Hao
    Barry, William T.
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth A.
    Partridge, Ann H.
    Hudis, Clifford A.
    Krop, Ian
    Burstein, Harold J.
    Winer, Eric P.
    Tolaney, Sara M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (02) : 303 - 310
  • [7] Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)70077-9, 10.1016/S1470-2045(08)60348-7]
  • [8] Patient-Reported Outcomes Over 5 Years After Whole-or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial
    Bhattacharya, Indrani S.
    Haviland, Joanne S.
    Kirby, Anna M.
    Kirwan, Cliona C.
    Hopwood, Penelope
    Yarnold, John R.
    Bliss, Judith M.
    Coles, Charlotte E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 305 - +
  • [9] How Low Can You Go? The Radiobiology of Hypofractionation
    Brand, D. H.
    Kirby, A. M.
    Yarnold, J. R.
    Somaiah, N.
    [J]. CLINICAL ONCOLOGY, 2022, 34 (05) : 280 - 287
  • [10] Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy
    Braunstein, Lior Z.
    Taghian, Alphonse G.
    Niemierko, Andrzej
    Salama, Laura
    Capuco, Alexander
    Bellon, Jennifer R.
    Wong, Julia S.
    Punglia, Rinaa S.
    MacDonald, Shannon M.
    Harris, Jay R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (01) : 173 - 179